A Phase 2b Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy Protocol No. D5170C00002

This study is for patients with moderate to severe Crohn’s Disease who have failed or are intolerant to one or more anti-TNFα therapies.  This study will test the safety and effectiveness of active study drug MEDI2070 against placebo (no study drug) which will be delivered either through intravenous (IV) method, through subcutaneous (under the skin) injections, or using both methods. After 28 weeks, patients will have the opportunity to receive open-label (active study drug) for 24 weeks.

It is hoped that this will help to reduce inflammation (swelling and irritation) within the intestines and relieve symptoms of Crohn’s disease.


Sponsor: MedImmune /Astrazeneca

Keywords: "GI", Crohn’s Disease, Crohn’s; "CD"; gastrointestinal, "IBD", inflammatory bowel disease
Gastrointestinal (GI)
Kevin Casey, MD
Center for Clinical Research